Narwhal Capital Management Has $17.87 Million Stock Holdings in Johnson & Johnson $JNJ

Narwhal Capital Management increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 19.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 96,371 shares of the company’s stock after purchasing an additional 15,755 shares during the quarter. Johnson & Johnson makes up approximately 1.3% of Narwhal Capital Management’s holdings, making the stock its 18th biggest holding. Narwhal Capital Management’s holdings in Johnson & Johnson were worth $17,869,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Johnson & Johnson by 1.3% during the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock worth $36,209,060,000 after buying an additional 3,085,180 shares in the last quarter. Geode Capital Management LLC grew its position in Johnson & Johnson by 2.1% during the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock worth $9,227,988,000 after acquiring an additional 1,225,676 shares during the last quarter. Norges Bank acquired a new stake in Johnson & Johnson during the 2nd quarter valued at $4,877,174,000. Bank of New York Mellon Corp raised its position in Johnson & Johnson by 2.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company’s stock valued at $3,635,832,000 after purchasing an additional 620,039 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Johnson & Johnson by 0.3% in the second quarter. Charles Schwab Investment Management Inc. now owns 18,951,337 shares of the company’s stock worth $2,894,979,000 after purchasing an additional 52,074 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on JNJ shares. Sanford C. Bernstein raised their target price on Johnson & Johnson from $193.00 to $208.00 and gave the company a “market perform” rating in a research note on Friday. UBS Group reissued a “buy” rating on shares of Johnson & Johnson in a report on Monday, January 5th. Wolfe Research boosted their target price on shares of Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a research note on Monday, January 5th. Bank of America upped their target price on shares of Johnson & Johnson from $204.00 to $220.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. Four analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $213.33.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $209.79 on Tuesday. The company has a market cap of $505.45 billion, a PE ratio of 20.25, a PEG ratio of 2.10 and a beta of 0.34. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $215.18. The company’s 50-day moving average is $203.34 and its two-hundred day moving average is $185.38.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.